Download PDF
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2018; 07(04): 240-243
DOI: 10.4103/sajc.sajc_241_17
ORIGINAL ARTICLE: Gynaecologic Cancers

Age-adjusted charlson comorbidity index and 30-day morbidity in pelvic surgeries

Authors

  • Sampada B. Dessai

    Department of Surgical Oncology, Malabar Cancer Center, Kannur, Kerala, India

  • R. Fasal

    Department of Surgical Oncology, Malabar Cancer Center, Kannur, Kerala, India

  • J. Dipin

    Department of Surgical Oncology, Malabar Cancer Center, Kannur, Kerala, India

  • D. Adarsh

    Department of Surgical Oncology, Malabar Cancer Center, Kannur, Kerala, India

  • Satheesan Balasubramanian

    Department of Surgical Oncology, Malabar Cancer Center, Kannur, Kerala, India

Financial support and sponsorship Nil.
Further Information
Also available at
 PDF Download Permissions and Reprints

Abstract

Introduction: Charlson comorbidity index (CCI) is a validated tool enabling clinicians for prediction of adverse events posttherapy. In this study, we planned to estimate the predictive value of age-adjusted CCI (ACCI) in assessing the perioperative complication in oncological patients undergoing major pelvic surgeries. Methods: This was a single arm, prospective, observational study, in which adult patients with pelvic malignancies undergoing pelvic surgeries were selected. The relationship between the ACCI and Grade 3–5 adverse events were tested using Fisher's test. Results: The rate of Grade 3–5 adverse event rate was 16.7% (11 patients, n = 66). Among the whole cohort, 11 patients (16.7%) had high score on ACCI. The rate of Grade 3–5 adverse events was higher in the cohort of patients with high ACCI score (45.5% vs. 10.9%, P = 0.014). The sensitivity, specificity and negative and positive predictive values were 45.5%, 89.1%, 89.1%, and 45.5%, respectively. Conclusion: ACCI can predict for postsurgical adverse events. It has a high negative predictive value for nonoccurrence of adverse events.

Key words

Adverse events - age adjusted Charlson comorbidity index - Charlson comorbidity index - complications - pelvic - surgeries


Publication History

Article published online:
21 December 2020

© 2018. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Yeole BB, Kurkure AP, Koyande SS. Geriatric cancers in India: An epidemiological and demographic overview. Asian Pac J Cancer Prev 2008;9:271-4.
  • 2 Read WL, Tierney RM, Page NC, Costas I, Govindan R, Spitznagel EL, et al. Differential prognostic impact of comorbidity. J Clin Oncol 2004;22:3099-103.
  • 3 Patil VM, Chakraborty S, Dessai S, Kumar SS, Ratheesan K, Bindu T, et al. Patterns of care in geriatric cancer patients – An audit from a rural based hospital cancer registry in Kerala. Indian J Cancer 2015;52:157-61.
  • 4 Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014;120:1290-314.
  • 5 Jiao YS, Gong TT, Wang YL, Wu QJ. Comorbidity and survival among women with ovarian cancer: Evidence from prospective studies. Sci Rep 2015;5:11720.
  • 6 Wells CK, Stoller JK, Feinstein AR, Horwitz RI. Comorbid and clinical determinants of prognosis in endometrial cancer. Arch Intern Med 1984;144:2004-9.
  • 7 Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51.
  • 8 Suidan RS, Leitao MM Jr., Zivanovic O, Gardner GJ, Long Roche KC, Sonoda Y, et al. Predictive value of the Age-Adjusted Charlson Comorbidity index on perioperative complications and survival in patients undergoing primary Debulking surgery for advanced epithelial ovarian cancer. Gynecol Oncol 2015;138:246-51.
  • 9 Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. J Biomed Inform 2014;48:193-204.
  • 10 Lee JY, Lee DH, Cho NH, Rha KH, Choi YD, Hong SJ, et al. Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy. Yonsei Med J 2014;55:316-23.
  • 11 Seo HJ, Yoon SJ, Lee SI, Lee KS, Yun YH, Kim EJ, et al. Acomparison of the Charlson comorbidity index derived from medical records and claims data from patients undergoing lung cancer surgery in Korea: A population-based investigation. BMC Health Serv Res 2010;10:236.
  • 12 Chang CM, Yin WY, Wei CK, Wu CC, Su YC, Yu CH, et al. Adjusted age-adjusted Charlson comorbidity index score as a risk measure of perioperative mortality before cancer surgery. PLoS One 2016;11:e0148076.
  • 13 Hsieh MC, Thompson T, Wu XC, Styles T, O'Flarity MB, Morris CR, et al. The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients. Cancer Med 2016;5:871-80.
  • 14 Tetsche MS, Dethlefsen C, Pedersen L, Sorensen HT, Norgaard M. The impact of comorbidity and stage on ovarian cancer mortality: A nationwide Danish cohort study. BMC Cancer 2008;8:31.
  • 15 Grann AF, Thomsen RW, Jacobsen JB, Nørgaard M, Blaakær J, Søgaard M, et al. Comorbidity and survival of Danish ovarian cancer patients from 2000-2011: A population-based cohort study. Clin Epidemiol 2013;5:57-63.